enGene Therapeutics Inc. (ENGN) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-07-31..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-07-31..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-07-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-07-31. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-07-31. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 96.26M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 17.36M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -136.65M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-31 | $96.26M | (m) | $17.36M | $-136.65M | (m) | (m) | (m) | (m) | (m) |
| 2026-04-30 | $98.75M | (m) | $12.13M | $-132.58M | (m) | (m) | (m) | (m) | (m) |
| 2026-01-31 | $96.76M | (m) | $10.64M | $-127.74M | (m) | (m) | (m) | (m) | (m) |
| 2025-10-31 | $94.48M | (m) | $9.65M | $-123.17M | (m) | (m) | (m) | (m) | (m) |
| 2025-07-31 | $74.03M | (m) | $8.70M | $-101.14M | (m) | (m) | (m) | (m) | (m) |
| 2025-04-30 | $63.01M | (m) | $7.58M | $-87.95M | (m) | (m) | (m) | (m) | (m) |
| 2025-01-31 | $52.65M | (m) | $6.84M | $-78.14M | (m) | (m) | (m) | (m) | (m) |
| 2024-10-31 | $38.31M | (m) | $5.32M | $-62.30M | (m) | (m) | (m) | (m) | (m) |
| 2024-07-31 | $32.71M | (m) | $7.02M | $-55.28M | (m) | (m) | (m) | (m) | (m) |
| 2024-04-30 | $25.07M | (m) | $5.60M | $-44.77M | $3.89M | (m) | (m) | -11.50× | Reported |
| 2024-01-31 | $18.43M | (m) | $3.72M | $-32.20M | $4.34M | (m) | (m) | -7.42× | Reported |
| 2023-10-31 | $16.46M | (m) | $3.45M | $-26.06M | $4.95M | (m) | (m) | -5.26× | Reported |
| 2023-07-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-04-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-01-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-10-31 | $15.47M | (m) | $116.00K | $-19.43M | $1.42M | (m) | (m) | -13.65× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |